edluar 10 mg podjezične tablete
meda pharma gmbh & co. kg - zolpidem - podjezična tableta - zolpidem 8,04 mg / 1 tableta - zolpidem
edluar 10 mg podjezične tablete
meda pharma gmbh & co. kg - zolpidem - podjezična tableta - zolpidem 8,04 mg / 1 tableta - zolpidem
edluar 10 mg podjezične tablete
meda pharma gmbh & co. kg - zolpidem - podjezična tableta - zolpidem 8,04 mg / 1 tableta - zolpidem
edluar 10 mg podjezične tablete
meda pharma gmbh & co. kg - zolpidem - podjezična tableta - zolpidem 8,04 mg / 1 tableta - zolpidem
edluar 5 mg podjezične tablete
meda pharma gmbh & co. kg - zolpidem - podjezična tableta - zolpidem 4,02 mg / 1 tableta - zolpidem
edluar 5 mg podjezične tablete
meda pharma gmbh & co. kg - zolpidem - podjezična tableta - zolpidem 4,02 mg / 1 tableta - zolpidem
levact 2,5 mg/ml prašek za koncentrat za raztopino za infundiranje
astellas pharma gmbh - bendamustinijev klorid - prašek za koncentrat za raztopino za infundiranje - bendamustinijev klorid 2,5 mg / 1 ml - bendamustin
propoven 10 mg/ml emulzija za injiciranje ali infundiranje
fresenius kabi austria gmbh. - propofol - emulzija za injiciranje/infundiranje - propofol 10 mg / 1 ml - propofol
deltyba
otsuka novel products gmbh - delamanid - tuberkuloza, odporna proti multidrugom - antimikobakterij - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 in 5. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.
mircera
roche registration gmbh - metoksi polietilen glikol-epoetin beta - anemia; kidney failure, chronic - antianemični preparati - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.